Submission on PBS Safeguards for Postmenopausal Women

We wrote to the Pharmaceutical Benefits Advisory Committee supporting the PBS listing of AndroFeme 1 for postmenopausal women with HSDD and pressed for strong safeguards to stop off label use in younger women.

We called for a firm age limit, specialist only prescribing, and an explicit exclusion of any gender affirming use to keep prescribing grounded in evidence and to prevent testosterone being diverted to biologically female adolescents.